{{Rsnum
|rsid=463426
|Chromosome=22
|position=21454896
|Orientation=plus
|GMAF=0.4385
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 63.7 | 29.2 | 7.1
| HCB | 23.0 | 51.9 | 25.2
| JPT | 28.6 | 53.6 | 17.9
| YRI | 17.7 | 44.2 | 38.1
| ASW | 21.1 | 43.9 | 35.1
| CHB | 23.0 | 51.9 | 25.2
| CHD | 24.8 | 43.1 | 32.1
| GIH | 27.7 | 52.5 | 19.8
| LWK | 14.5 | 54.5 | 30.9
| MEX | 19.0 | 46.6 | 34.5
| MKK | 10.9 | 43.6 | 45.5
| TSI | 48.5 | 40.6 | 10.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs463426
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.39, combined P value= 3.05E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470228
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs463426
|overall_frequency_n=80
|overall_frequency_d=128
|overall_frequency=0.625
|n_genomes=47
|n_genomes_annotated=0
|n_haplomes=67
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}